From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents
This review aims to discuss similarities and dissimilarities between BCR::ABL1-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historical...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-12-01
|
| Series: | EJC Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772610X25000923 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839641722915651584 |
|---|---|
| author | Sarah K. Tasian Judith M. Boer Monique L. den Boer |
| author_facet | Sarah K. Tasian Judith M. Boer Monique L. den Boer |
| author_sort | Sarah K. Tasian |
| collection | DOAJ |
| description | This review aims to discuss similarities and dissimilarities between BCR::ABL1-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with BCR::ABL1-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed. |
| format | Article |
| id | doaj-art-61ae2e6a62b34c228eddc65c4d0e9ba3 |
| institution | Matheson Library |
| issn | 2772-610X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Paediatric Oncology |
| spelling | doaj-art-61ae2e6a62b34c228eddc65c4d0e9ba32025-07-03T04:40:35ZengElsevierEJC Paediatric Oncology2772-610X2025-12-016100304From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescentsSarah K. Tasian0Judith M. Boer1Monique L. den Boer2Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Children’s Hospital of Philadelphia, Division of Oncology and Center for Childhood Research, Philadelphia, United States; University of Pennsylvania School of Medicine, Department of Pediatrics and Abramson Cancer Center, Philadelphia, United States; Corresponding author at: Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, Utrecht 3584 CS, the Netherlands.Princess Máxima Center for Pediatric Oncology, Utrecht, the NetherlandsPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht and Utrecht University, the NetherlandsThis review aims to discuss similarities and dissimilarities between BCR::ABL1-rearranged (Philadelphia chromosome-positive [Ph+]) and ABL-class fusion-driven BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL) in children and adolescents. Recent insights into the biology of these historically high-risk leukemias, modern laboratory diagnostics, current treatment approaches, potential causes of treatment failure, emerging new targeted therapies and immunotherapeutic approaches for patients will be discussed. While the primary focus of this review is upon children and adolescents with BCR::ABL1-positive and ABL-class ALL, extended knowledge from recent adult clinical trials will also be addressed.http://www.sciencedirect.com/science/article/pii/S2772610X25000923ABL-classAcute lymphoblastic leukemiaBCR::ABL1BCR::ABL1-likeChildrenClinical trials |
| spellingShingle | Sarah K. Tasian Judith M. Boer Monique L. den Boer From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents EJC Paediatric Oncology ABL-class Acute lymphoblastic leukemia BCR::ABL1 BCR::ABL1-like Children Clinical trials |
| title | From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents |
| title_full | From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents |
| title_fullStr | From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents |
| title_full_unstemmed | From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents |
| title_short | From the bench of molecular understanding to the bedside of optimal therapy for BCR::ABL1 and ABL-class acute lymphoblastic leukemia in children and adolescents |
| title_sort | from the bench of molecular understanding to the bedside of optimal therapy for bcr abl1 and abl class acute lymphoblastic leukemia in children and adolescents |
| topic | ABL-class Acute lymphoblastic leukemia BCR::ABL1 BCR::ABL1-like Children Clinical trials |
| url | http://www.sciencedirect.com/science/article/pii/S2772610X25000923 |
| work_keys_str_mv | AT sarahktasian fromthebenchofmolecularunderstandingtothebedsideofoptimaltherapyforbcrabl1andablclassacutelymphoblasticleukemiainchildrenandadolescents AT judithmboer fromthebenchofmolecularunderstandingtothebedsideofoptimaltherapyforbcrabl1andablclassacutelymphoblasticleukemiainchildrenandadolescents AT moniqueldenboer fromthebenchofmolecularunderstandingtothebedsideofoptimaltherapyforbcrabl1andablclassacutelymphoblasticleukemiainchildrenandadolescents |